Treatment for interstitial lung disease
AssigneeUnited Therapeutics Corporation
InventorsLeigh Peterson, Peter Smith, Chunqin Deng
Life of this patent
Estimating the term…
Abstract
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
Claims24
A method of improving exercise capacity in a patient having pulmonary hypertension associated with interstitial lung disease, comprising administering by inhalation to the patient having pulmonary hypertension associated with interstitial lung disease an effective amount of at least 15 micrograms up to a maximum tolerated dose of treprostinil or a pharmaceutically acceptable salt thereof in a single administration event that comprises at least 6 micrograms per breath, wherein 4 single administration events are performed per day with a nebulizer comprising an inhalation solution comprising treprostinil or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.